TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in subretinal thickness (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gatifloxacin concentration in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in 24-h heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum UA level <5.0 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grade 3/4 non-hematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Decreased levels of fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreased levels of prothrombin fragments F(1+2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreased levels of plasmin/antiplasmin complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bleeding upon probing (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: teacher-reported self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sugar-sweetened beverage intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load below 50 copies/ml at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PSC Mayo risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alkaline phosphatase (ALP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient psychological outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decline in verbal memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: decline in verbal fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: conversion to dementia
Endpoint domain: Mortality/survival
Primary endpoint: postinfusion pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: punctate hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence Episode Frequency (IEF) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGI-I ratings (much/very much better)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intracranial pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived Barriers to Healthy Eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat gram intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of DLC
Endpoint domain: Adverse events/effects
Primary endpoint: Death or MI at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Prediction of tumor behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Life quality of patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: urinary excretion of RBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Test-retest reliability of cognitive outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Anxiety Inventory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in person-centered teaching behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps H-reflex facilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SPADI score at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work status at 1 year follow-up
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lack of concentration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Restlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modification of treatment proposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of fires
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of smoke detectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fires confined to the object of origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hmax:Mmax ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds Ratios for case-patients versus control-patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in itching of seborrhoeic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and self-assessment scores for seborrhoeic dermatitis and dandruff
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days of migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isolated motor functions of the paretic arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma DHA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erythrocyte phospholipid DHA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LC‐PUFA synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Function (PF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back Pain (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No pain experienced during cyclocryotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Breath isoprene production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GP IIb/IIIa receptor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet aggregation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Competence in debridement skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Chronic success rates after 9-month evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scotopic contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher order aberrations (HOAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean refractive error (MRSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of MedDRA primary SOCs
Endpoint domain: Adverse events/effects
Primary endpoint: Deep vein thrombosis (DVT) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ET level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CGRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: local recurrence and distant metastasis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Post-intervention MDI misuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day acute health-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in morning peak expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diastolic pulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-month primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month CD-TLR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of surgical glove perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difficulty using blunt needles
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impairments of vigilance and psychomotor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term outcomes of elderly patients suffering from chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term hypoalgesia during exercise sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS nausea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic seated balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-interval H-reflex facilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of clinically suspected infection
Endpoint domain: Adverse events/effects
Primary endpoint: Electroencephalographic spectral power density in the beta-band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peak oxygen consumption during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: O2Hb of SCM and BC muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum high-sensitivity C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Combined end point of death, stroke, or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Self-assessed health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increased pelvic muscle contraction strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in QLS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fewer episodes of urine leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak FEV1 add-on response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: peak FVC add-on response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma concentrations of biologically active oxylipins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intermittent pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ghrelin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pancreatic polypeptide response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma response of 2-arachidonoylglycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PACU bypass rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative height difference correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma IGF‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma IGFBP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: composite AKS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neck Disability Index points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of recurrent VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of major or nonmajor clinically relevant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: improvements in clinical evaluation scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 50-70% response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of telecommunication link on interventional procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCCB and clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: late preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: diabetes incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of emphysema measured by PD15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean renal artery enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean renal cortical enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cortex-to-medulla contrast difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Restoration of sinus rhythm after first shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restoration of sinus rhythm after second shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: relief in obstructive and irritative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased serum FGF-23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in the required dose of saccharated ferric oxide
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resuscitation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tracheal catheter indwelling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dosage of Propofol and Nicardipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for antihypertensive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful ablation site prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in radiofrequency pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ablation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fluoroscopic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nurses' attitudes towards dysphagia screening
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: relative Constant score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tendon integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burning levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EAPP measured on a VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of anesthetic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical success rate based on cessation of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor complications experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Total days of birth-related hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area of pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) after PCNL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: quicker recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly urine samples negative for illicit opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increase in lumbosacral spine mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V95 coverage index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTV overlap index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte protection effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of P‐MDA and E‐MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities of Na+ ‐K+ ‐ATPase and Ca+ ‐Mg2+ ‐ATPase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: adherence to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of FRM practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FRM confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Worry about food running out
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximum observed plasma concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration‐time curve (AUC(last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half‐life (t(1/2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasodilator response to dipyridamole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerance to ischemia-reperfusion injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of any clinical fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of osteoporosis-associated nonhip fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: adverse reactions to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Self-perceptions of ageing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tear Film Break-Up Time (TFBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Meibum grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Tarsal conjunctival temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Postoperative shivering score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rate of restorations
Endpoint domain: Mortality/survival
Primary endpoint: Marginal adaptation deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inlay fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bevacizumab use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall CGI-BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BISS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weighted mean TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV stigma levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of 3+ cardiovascular risk factors (CVRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Actuarial risk of CMV antigenemia at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Actuarial risk of developing acute GvHD grade II-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Actuarial 1 year transplant-related mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Flanker test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Category fluency test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reducing pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improving ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning